Skip to main content
Article thumbnail
Location of Repository

Structure and function of the human Gly1619Arg polymorphism of M6P/IGF2R domain 11 implicated in IGF2 dependent growth

By Dellel Rezgui, Christopher Williams, Sharon A Savage, Stuart N Prince, Oliver J Zaccheo, E Yvonne Jones, Matthew P Crump and A Bassim Hassan

Abstract

The mannose 6-phosphate/IGF 2 receptor (IGF2R) is comprised of 15 extra-cellular domains that bind IGF2 and mannose 6-phosphate ligands. IGF2R transports ligands from the Golgi to the pre-lysosomal compartment and thereafter to and from the cell surface. IGF2R regulates growth, placental development, tumour suppression and signalling. The ligand IGF2 is implicated in the growth phenotype, where IGF2R normally limits bioavailability, such that loss and gain of IGF2R results in increased and reduced growth respectively. The IGF2R exon 34 (5002A>G) polymorphism (rs629849) of the IGF2 specific binding domain has been correlated with impaired childhood growth (A/A homozygotes). We evaluated the function of the Gly1619Arg non-synonymous amino acid modification of domain 11. NMR and X-ray crystallography structures located 1619 remote from the ligand binding region of domain 11. Arg1619 was located close to the fibronectin type II (FnII) domain of domain 13, previously implicated as a modifier of IGF2 ligand binding through indirect interaction with the AB loop of the binding cleft. However, comparison of binding kinetics of IGF2R, Gly1619 and Arg1619 to either IGF2 or mannose 6-phosphate revealed no differences in ‘on’ and ‘off’ rates. Quantitative PCR, 35S pulse chase and flow cytometry failed to demonstrate altered gene expression, protein half-life and cell membrane distribution, suggesting the polymorphism had no direct effect on receptor function. Intronic polymorphisms were identified which may be in linkage disequilibrium with rs629849 in certain populations. Other potential IGF2R polymorphisms may account for the correlation with childhood growth, warranting further functional evaluation

Topics: Regular papers
Publisher: Society for Endocrinology
OAI identifier: oai:pubmedcentral.nih.gov:2659294
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2005). Haploview: analysis and visualization of LD and haplotype maps.
    2. (2002). Structure of a functional IGF2R fragment determined from the anomalous scattering of sulfur.
    3. (2008). Structure and functional analysis of the IGF-II/IGF2R interaction.
    4. (1999). Disruption of ligand binding to the insulin-like growth factor II/mannose 6-phosphate receptor by cancer-associated missense mutations.
    5. (2000). Dimerization of the insulin-like growth factor II/mannose 6-phosphate receptor.
    6. (1994). A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis.
    7. (1989). Chicken and Xenopus mannose 6-phosphate receptors fail to bind insulin-like growth factor II.
    8. (1991). Extracellular release as the major degradative pathway of the insulin-like growth factor II/mannose 6-phosphate receptor.
    9. (2004). Metalloproteinase pregnancy-associated plasma protein A is a critical growth regulatory factor during fetal development.
    10. (2003). Loss of IGF2 imprinting: a potential marker of colorectal cancer risk.
    11. (1990). High level expression in Chinese hamster ovary cells of soluble forms of CD4 T lymphocyte glycoprotein including glycosylation variants.
    12. (1995). M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity.
    13. (1995). A
    14. (1991). Cellular activation of latent transforming growth factor beta requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor.
    15. (1999). Altered ligand binding by insulin-like growth factor II/mannose 6-phosphate receptors bearing missense mutations in human cancers.
    16. (2005). Insulin-like growth factor ligands, receptors, and binding proteins in cancer.
    17. (2007). A second generation human haplotype map of over 3.1 million SNPs.
    18. (2002). Increased insulin-like growth factor (IGF)-II and IGF/IGF-binding protein ratio in prepubertal constitutionally tall children.
    19. (2003). Mannose 6-phosphate receptors: new twists in the tale. Nature Reviews.
    20. Sun G & Dahms NM 2002a Identification of residues essential for carbohydrate recognition by the insulin-like growth factor II/mannose 6-phosphate receptor.
    21. NM 2002b Localization of the carbohydrate recognition sites of the insulin-like growth factor II/mannose 6-phosphate receptor to domains 3 and 9 of the extracytoplasmic region.
    22. (1996). M6P/IGF2, receptor: a candidate breast tumor suppressor gene.
    23. (2006). Soluble IGF2 receptor rescues Apc(Min/C) intestinal adenoma progression induced by Igf2 loss of imprinting.
    24. (2008). Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer.
    25. (2007). Insulin-like growth factor 2 (IGF2) and IGF2 receptor gene variants are associated with fetal growth.
    26. (2009). IGF2R domain 11 G1619R polymorphism . D REZGUI and others 355 www.endocrinology-journals.org Journal of Molecular Endocrinology
    27. (1989). Insulin-like growth factor-II (IGF-II) inhibits both the cellular uptake of beta-galactosidase and the binding of beta-galactosidase to purified IGF-II/mannose 6-phosphate receptor.
    28. (1990). Beta-galactosidase decreases the binding affinity of the insulin-like-growth-factorII/mannose-6-phosphate receptor for insulin-like-growth-factor II.
    29. (2001). Mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R) variants in American and Japanese populations.
    30. (2004). The multiethnic cohort study: exploring genes, lifestyle and cancer risk. Nature Reviews.
    31. (2000). RLM6P/IGF2R, is mutated in squamous cell carcinoma of the lung.
    32. (2005). Domain interactions of the mannose 6-phosphate/insulin-like growth factor II receptor.
    33. (2001). Real time kinetics of insulinlike growth factor II (IGF-II) interaction with the IGF-II/mannose 6-phosphate receptor: the effects of domain 13 and pH.
    34. (1996). Efstratiadis A
    35. (2004). A CCR2-V64I polymorphism affects stability of CCR2A isoform.
    36. (2006). SNP500Cancer: a public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes.
    37. (2005). Genetic variation in the type 2 insulin-like growth factor receptor gene and disparity in childhood height.
    38. (2007). Analysis of genes critical for growth regulation identifies Insulin-like Growth Factor 2 Receptor variations with possible functional significance as risk factors for osteosarcoma.
    39. (2004). Misfolding diverts CFTR from recycling to degradation: quality control at early endosomes.
    40. (2005). The CCPN, data model for NMR spectroscopy: development of a software pipeline.
    41. (1994). Regulation of embryonic growth and lysosomal targeting by the imprinted Igf2/Mpr gene.
    42. (2007). Structural insights into the interaction of insulin-like growth factor 2 with IGF2R domain 11.
    43. (2001). Non-imprinted Igf2r expression decreases growth and rescues the Tme mutation in mice.
    44. (2003). Tissue-specific inactivation of murine M6P/IGF2R.American
    45. (1993). Functional polymorphism in the parental imprinting of the human IGF2R gene.
    46. (1999). The kangaroo cation-independent mannose 6-phosphate receptor binds insulinlike growth factor II with low affinity.
    47. (1999). The rate of internalization of the mannose 6-phosphate/insulin-like growth factor II receptor is enhanced by multivalent ligand binding.
    48. (2001). Epigenetic change in IGF2R is associated with fetal overgrowth after sheep embryo culture.
    49. (2006). Kinetics of insulin-like growth factor II (IGF-II) interaction with domain 11 of the human IGF-II/mannose 6-phosphate receptor: function of CD and AB loop solvent-exposed residues.
    50. (2009). Made available online as an Accepted

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.